MBRX Moleculin Biotech Inc
Company Analysis
Latest News
🔴 Moleculin Biotech is trading 6.7% down in after-hours trading with no verified company-specific negative announcement identified
Moleculin Biotech is trading 6.7% down at $0.42 after-hours, with no verified company-specific negative announcement identified. - It closed at $0.45 on...
🟢 Moleculin Biotech is trading 5.2% up today after Q2 earnings and strong interim MIRACLE data
- Moleculin Biotech is trading at $0.45, up +5.16% on August 11, 2026. - The company announced its Q2 2026 earnings today. - Investor enthusiasm continues...
🟢 Moleculin Biotech is trading 6.88% up in after-hours trading on positive interim MIRACLE leukemia data
Moleculin Biotech is trading 6.88% up at $0.46 after the August 10, 2026 regular session closed at $0.43, with the move appearing linked to lingering...
Moleculin's Leukemia Drug Shows Promise in Hard-to-Treat Patients, but Can a Sub-Penny Stock Survive Its Own Dilution?
Shares shifted as Moleculin Biotech climbed 10% to $0.45 on lingering enthusiasm from July 31 interim data showing its experimental cancer drug working in...
🟢 Moleculin Biotech is trading 10% up today after 37% blinded composite complete remission data
Moleculin Biotech is trading 10% up now at $0.45 after positive blinded MIRACLE AML data continued attracting investor attention. - The company has not...
🟢 Moleculin Biotech is trading 5% up today amid positive blinded MIRACLE AML data
Moleculin Biotech is trading at $0.43, up +5.03% from the August 7, 2026 close of $0.41, amid positive blinded MIRACLE AML data. • No new company announcement...
Moleculin Biotech Inc Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
Moleculin Biotech is expected to report a Q2 2026 loss of $1.55 per share on zero revenue, with the current stock price of $4.85 trading significantly below...
🔴 Moleculin Biotech is trading 5% down today after its $9.3 million public offering
Moleculin Biotech is trading at $0.37 (-5.13%) as its recent $9.3 million public offering continues to weigh on shares. - Completed on August 3, 2026, the...
🟢 Moleculin Biotech is trading 6% up today as XBI rises 2.09%
Moleculin Biotech is trading 6.41% up at $0.41, supported by a broader biotech rally, with XBI up 2.09% during regular trading. - The stock remains volatile...
🔴 Moleculin Biotech is trading 5.5% down today as selling pressure from $9.3M public offering continues
Moleculin Biotech is trading 5.5% down at $0.39 as the stock continues to absorb heavy selling pressure tied to its recently announced $9.3 million public...
🟢 Moleculin Biotech is trading 7.23% up today in a volatile bounce from deeply oversold levels
Moleculin Biotech is trading at $0.44 (+7.23%) as shares stage a recovery following a sharp multi-day collapse triggered by a $9.3 million public offering and...
🔴 Moleculin Biotech is trading 5.2% down today on dilution pressure from a $9.3M public offering
Moleculin Biotech is trading 5.2% down today at $0.41 following a sharply discounted $9.3 million public offering that triggered a major dilution-driven...
🔴 Moleculin Biotech is trading 5.7% down today following a discounted $9.3 million public offering
Moleculin Biotech is trading at $0.40 (-5.69%) in pre-market following a sharp post-offering selloff triggered by a discounted $9.3 million public offering. •...
🔴 Moleculin Biotech is trading 10.2% down today amid post-offering volatility and dilution worries
Moleculin Biotech is trading at $0.38 (10.2% down) following a sharp pullback in thin after-hours trading. • The decline extends a multi-day selloff...
🔴 Moleculin Biotech is trading 6.2% down today as post-offering volatility and dilution concerns persist
Moleculin Biotech is trading at $0.40 (6.2% down) in after-hours sessions, extending volatility following its recent $9.3 million discounted public...
🟢 Moleculin Biotech is trading 5.4% up today as shares stabilize after a $9.3M public offering selloff
Moleculin Biotech is trading at $0.42 (5.4%) up today as the stock stabilizes following a sharp multi-day selloff triggered by a deeply discounted $9.3 million...
🔴 Moleculin Biotech is trading 35% down today after pricing $9.3M public offering at a steep discount
Moleculin Biotech is trading 35% down at $0.29 after pricing a $9.3 million public offering at a steep discount to recent market levels. • The offering,...
🔴 Moleculin Biotech Plunges 21.6% After Pricing $9.3 Million Public Offering at $0.75 Per Share, Despite Positive Interim Trial Data
Moleculin Biotech is trading 21.6% down at $0.80 today, extending a sharp multi-day slide. • The company announced the pricing of a $9.3 million public...
Moleculin Reports Positive Interim Data from MIRACLE AML Trial, Showing 37% Remission Rate
Moleculin Biotech announced updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin for treating relapsed or...
Moleculin's Leukemia Drug Showed Promise — So Why Is the Stock in Freefall, and Can This Company Survive Long Enough to Benefit?
Shares of Moleculin Biotech cratered 60% in four trading days, sliding from $2.19 to $0.86, after the company filed a new registration statement to sell shares...